Evidence map›Paper›PMID 41961819›Full record

Trial reportProceedings of the National Academy of Sciences of the United States of America2026

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.

Noor M Abdulkareem, Yan Jiang, Yuan Qi, Xuan Liu, Xiaomei Zhang, Shirong Cai, Jiansu Shao, Sabrina Jeter-Jones, Amanda L Rinkenbaugh, Chun-Chun Cheng and 5 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Noor M Abdulkareem *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0003-0189-3069
Yan Jiang *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Yuan QiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0001-9718-7593
Xuan LiuDepartment of Integrative Biology and Pharmacology, Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030.
Xiaomei ZhangDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Shirong CaiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jiansu ShaoDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Sabrina Jeter-JonesDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Amanda L RinkenbaughDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Chun-Chun ChengDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Faiza HancockDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jill SchwartzDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jennifer K LittonDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jeffrey T ChangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Helen Piwnica-WormsDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0003-4210-6738

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Project 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI BILD, ANDREA HOPE · 2017 to 2021
$10.5M
NCI NIH HHS P30 CA016672NCI NIH HHS U54 CA209978
6 · The paper itself

Abstract

Intrinsic and acquired resistance to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) remains a major barrier in treating homologous recombination (HR) repair-deficient tumors, including those with germline or somatic

Indexed as

Ataxia Telangiectasia Mutated ProteinsDrug Resistance, NeoplasmPhthalazinesSTAT3 Transcription FactorTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceNeoadjuvant TherapyPoly(ADP-ribose) Polymerase InhibitorsSignal TransductionXenograft Model Antitumor AssaysAtaxia Telangiectasia Mutated ProteinsPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsSTAT3 protein, humanSTAT3 Transcription FactortalazoparibBRN2PARP inhibitorPDX modelsSHLD2triple-negative breast cancer

Identifiers

PMID41961819
PMCPMC13099559

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.